References
- Widal F, Abrami P, Lermoyez J. First complete de-scription of the aspirin idiosyncrasy-Aspirine asthma-nasal polyposis syndrome (plus urticaria) 1922. J Asthma 1987; 24: 297–300.
- Samter M, Beers RF. Concerning the nature of intoler-ance to aspirin. J Allergy 1967; 40: 281–93.
- Settipane GA. Aspirin and allergic disease: a review Am J Med 1983; 74: 102–9.
- Dahlén B, Dahlén SE. Intolerance reactions to NSAIDs. In: Basomba A, Sastre J: ECACI '95 Pro-ceedings I; Bologna 1995: 821–8.
- Szczeklik A. Aspirin-induced asthma: an update and novel findings. Adv Prostaglandin Thromboxane Leukot Res 1994; 22: 185–98.
- Knapp HR, Sladek K, Fitzgerald GA. Increased excre-tion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med 1992; 119: 48–51.
- Wigand ME, Hosemann W. Microsurgical treatment of recurrent nasal polyps. Rhinol 1989; 8: 25–30.
- Schmitz-Schumann M, Juhl E, Costabel U, et al. Anal-getikaprovokationsproben bei Analgetika-Asthma-Syn-drom. Atemwegs- und Lungenkrankheiten 1985; 11: 479–86.
- Reinke M, Hoppe U, Röder T, Bestmann HJ, Mollen-hauer J, Brune K. A monoclonal antibody against the sulfidopeptide leukotrienes LTC4, LTD4 and LTE4. Biochem Biophys Acta 1991; 1081: 274–8.
- Brune K, Reinke M, Lenz R, Peskar BA. Monoclonal antibodies against E- and F-type prostaglandins. FEBS 1985; 2644 (189): 46–50.
- Ogino S, Irifune M, Harada T, Kikumori H, Mat-sunaga T. Arachidonic acid metabolites in human nasal polyps. Acta Otolaryngol (Stockh) 1993; 501: 85–7.
- Yamashita T, Tsuji H, Maeda N, Tomoda K, Ku-mazawa T. Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinol Suppl 1989; 8: 15–24.
- Dahlén SE, Dahlén B, Kumlin M, Björck T, Ihre E, Zetterström 0. Clinical and experimental studies of leukotriens as mediators of airway obstruction in hu-mans. Adv Prostaglandin Thromboxane Leukot Res 1994; 22: 155–66.
- Björck T, Harada Y, Dahlén B, et al. Further evidence that leukotrienes are the major mediators of allergic constriction in human bronchi. Adv Prostaglandin Thromboxane Leukot Res 1990; 21: 429–33.
- Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of as-pirin sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–51.
- Kumlin M, Dahlèn B, Björck T, Zetterström 0, Granström E, Dahlèn SE. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in re-sponse to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis 1992; 146: 96–103.
- Sladek K, Dworski R, Soja J, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant pa-tients with asthma after aspirin challenge. Am J Resp Crit Care Med 1994; 149: 940–6.
- Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Arachidonic acid metabolism in monocytes of aspirin-sensitive asthmatis patients before and after oral aspirin challenge. J Allergy Clin Immunol 1992; 90: 636–45.
- Szczeklik A. Prostaglandin E2 and aspirin-induced asthma. Lancet 1995; 345: 1056.
- Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin induced asthma. Am J Resp Crit Care Med 1996; 153: 567–71.
- Chung KR Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J 1995; 8: 1203–13.
- Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin induced asthma. Thorax 1994; 49: 749–56.
- Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and uri-nary LTE4 excretion in aspirin-sensitive asthma. Am J Resp Crit Care Med 1996; 153: 572–5.
- Schafer D, Lindenthal U, Wagner M, Bölcskei P, Baenkler HW. PGE2 inhibits pLT and TXB-release of human lung biopsy specimens. Allergy 1995; 50 (Suppl 26): 268.
- Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 1995; 96: 148–56.